RxDoctor Payments Data

Dalana Lane, NP

Nurse Practitioner · Independence, VANPI 1487284840

Payments from drug & device makers

$556in general payments, 2019–2025

Across 12 payments — averaging $46.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$179
  • Otsuka America Pharmaceutical, Inc.$160
  • Amgen$113
  • Novo Nordisk$49
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$21
  • Lilly USA, LLC$19
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$556100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$556 in reported general payments places this provider in the 75th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$111,669
Medicare patients
337
Services billed
1,543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$17,153
FarxigaDapagliflozin Propanediol16$10,456
Tamsulosin Hcl20$522
Atorvastatin Calcium55$478
Memantine Hcl12$476
Rosuvastatin Calcium23$447
Albuterol Sulfate HfaAlbuterol Sulfate19$423
Pantoprazole Sodium18$405
Losartan Potassium33$397
Levothyroxine Sodium32$345
Omeprazole13$310
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst24$302
Metoprolol Succinate20$298
Gabapentin17$249
Donepezil Hcl19$218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$17,15322 claims
AstraZenecaFarxiga$179$10,45616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Independence

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →